Network meta analysis of first-line therapy for advanced EGFR mutation positive non-small-cell lung cancer: updated overall survival
| Autor: | MeganS Farris, Keith D. Wilner, Malaika Pastel, Devon J. Boyne, Kelly A Larkin-Kaiser, Jasmina I Ivanova, Tayler Scory, Joseph C. Cappelleri |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty Lung Neoplasms Afatinib Network Meta-Analysis Disease-Free Survival Erlotinib Hydrochloride 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Gefitinib Epidermal growth factor Carcinoma Non-Small-Cell Lung Internal medicine medicine Humans Osimertinib 030212 general & internal medicine Lung cancer Protein Kinase Inhibitors Neoplasm Staging Quinazolinones Randomized Controlled Trials as Topic Acrylamides Aniline Compounds business.industry Hazard ratio Bayes Theorem General Medicine medicine.disease Dacomitinib respiratory tract diseases ErbB Receptors chemistry Gain of Function Mutation 030220 oncology & carcinogenesis Erlotinib business medicine.drug |
| Zdroj: | Future Oncology. 16:3107-3116 |
| ISSN: | 1744-8301 1479-6694 |
| DOI: | 10.2217/fon-2020-0541 |
| Popis: | Aim: To update overall survival (OS) results from a previous network meta analysis comparing the relative clinical efficacy of epidermal growth factor receptor-targeted tyrosine kinase inhibitors ( EGFR TKIs) for EGFR mutation positive ( EGFR+) advanced non-small-cell lung cancer (NSCLC). Materials & methods: A Bayesian network meta analysis was conducted using updated/mature randomized controlled trial OS results in response to first-line EGFR TKI therapies. Results: Dacomitinib showed a numerical improvement of OS relative to other EGFR TKIs: afatinib (hazard ratio [HR]: 0.87; 95% credible interval [CrI]: 0.61–1.24), erlotinib (HR: 0.79; 95% CrI: 0.44–1.42), gefitinib (HR: 0.75; 95% CrI: 0.59–0.95) and osimertinib (HR: 0.94; 95% CrI: 0.68–1.29). Conclusion: Dacomitinib should be considered as a first-line treatment option for patients diagnosed with advanced EGFR+ NSCLC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|